The Cole Eye Institute Imaging Summit took place on Friday, August 9, 2016 prior to the American Society of Retina Specialists (ASRS).

The is a CME symposium focusing on new advances in OCT imaging with hands-on imaging sessions. Attendees will be able to discuss current topics in tomography and imaging with a faculty of distinguished peers. Ocular imaging technology is an area of intense innovation with every year bringing better and more options to the clinic. Outcomes in vision care are best when ophthalmologists, retina specialists, and other eye care health practicioners remain informed of the latest ocular imaging capabilities. Following this course, learners will be able to better select appropriate diagnostic testing and better interpret those tests to improve patient care. Additionally, learners will be made aware of new and exciting modalities of ophthalmic imaging that can be implemented into their clinical practice.

Session Topics

  • What’s Next in Imaging? – SriniVas R. Sadda, MD
  • Novel Approaches to Fluorescein Angiography Analysis -Justis P. Ehlers, MD
  • OCT Angiography: Clinical Systems, Software, and Interpretation – Jay S. Duker, MD
  • OCT􀀁Angiography, OCT, FFA Correlation: Information or Misinformation? Pravin U. Dugel, MD
  • Panel Case-Based Discussion: OCT Angiography vs Fluorescein Angiography — When and Why to Use Them? – Moderator: Sunil K. Srivastava, MD

Emerging Approaches in Visualization and Image Analysis

  • Emerging Approaches in Visualization and Image Analysis

    Drs. Dugel; Duker; Ehlers; Kaiser; Sadda, and Srivastava
Target Audience

This activity is designed to meet the educational needs of Physicians (eg, Comprehensive Ophthalmologists, Retina Specialists, and Optometrists), Second-Year Fellows, Technicians, Ophthalmic Photographers and other healthcare professionals.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • List the current imaging machines available.
  • Assess the current clinical utility of OCTA.
Method of Participation

Statements of credit will be awarded based on the participant’s attendance. A statement of credit will be available upon completion of an online evaluation/claimed credit form available at

Please claim your credit by September 23, 2017.

If you have questions about this CME activity, please contact AKH Inc. at


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This activity is supported by an educational grant from: Alcon, Inc.; Bayer; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Faculty Disclosures

Pravin U. Dugel, MD

  • Consultant: Abbott/ Abbott Medical Optics; Aerpio Therapeutics; Alcon, a Novartis company; Alimera Sciences; Allergan; Annidis Inc.; Acucela Inc.; ArcticDx Inc.; Avalanche Biotechnologies, Inc.; Clearside Biomedical, Inc.; Digisight Technologies; Dose Medical Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Graybug Vision; Lutronic; Lux BioScience Inc; Neurotech USA; Novartis; OD-OS Inc.; Omeros; Ophthotech Corporation; Opthea; Optovue, Inc; ORA, Inc.; Regeneron Pharmaceuticals, Inc.; Pentavision LLC; Shire Human Genetic Therapies; Stealth BioTherapeutics; ThromboGenics NV; Topcon Medical Systems, Inc.
  • Stock: Alimera Sciences; Aerpio Therapeutics; Annidis Inc.; Digisight Technologies; Ophthotech Corporation; TrueVision

Jay S. Duker, MD

  • Board of Directors: Eleven Biotherapeutics
  • Consultant: Allergan; Aura Biosciences, Inc.; Bausch + Lomb; CoDa Therapeutics, Inc; Lumenis; Omeros Corporation; Santen Pharmaceutical; ThromboGenics NV
  • Contracted Research: Carl Zeiss Meditec, Inc.; Optovue, Inc
  • Stock: Hemera Biosciences Inc.; Ophthotech Corporation

Justis P. Ehlers, MD

  • Consultant: Alcon, a Novartis company; Bioptigen Inc; Carl Zeiss Meditec, Inc.; Leica Biosystems Nussloch GmbH; Santen Pharmaceutical; ThromboGenics NV
  • Contracted Research: Genentech, Inc.; Regeneron Pharmaceuticals, Inc.; ThromboGenics NV
  • Royalty: Bioptigen Inc; Synergetics Inc.

SriniVas R. Sadda, MD

  • Consultant: Allergan; Bausch + Lomb; Carl Zeiss Meditec, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Santen Pharmaceutical

Sunil K. Srivastava, MD

  • Consultant: Allergan; Bausch + Lomb; Carl Zeiss Meditec, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Santen Pharmaceutical
Planner Disclosures

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditations

  • Nothing to Disclose

MCME Global Staff and Planners

  • Nothing to Disclose

AKH Staff and Planners

  • Nothing to Disclose

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.

Advancing Knowledge in Healthcare    mcme-logo



Please answer the following pre-questions before moving on to the session presentations.

First Name*
Last Name*

Advantages of swept source OCT over existing spectral domain OCT devices include all of the following EXCEPT:

Higher speed
Higher axial resolution
Higher sensitivity
Deeper penetration

OCTA’s current limitations include:

High cost of the hardware
Artifacts making interpretation difficult
Small field of view
Lack of dye leakage
All of the above